title: A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases.
abstract: Hemibody irradiation (HBI) in a single exposure is an effective and safe technique for palliation of symptoms due to widespread bony metastases (RTOG 78-10). The present study (82-06) sought to explore the possibility that HBI added to local-field irradiation might delay the onset of metastases in the hemibody effected, as assessed by bone scans and X rays, and decrease the frequency of further treatment. The results of this clinical trial establish that 800 cGy of HBI is indeed causes micro-metastases to regress, perhaps completely. A total of 499 patients were randomized to receive either HBI or no further treatment following completion of standard palliative local field irradiation (300 cGy x 10) to the symptomatic site. Improvement was seen in time-to-disease progression at one year, 35% for local + HBI versus 46% on the local-only control arm. Time-to-new disease in the targeted hemibody was also improved. At one year, 50% of patients on the local + HBI arm showed new disease compared to 68% on the local-only arm. Furthermore, the median time-to-new disease within the targeted HBI area was 12.6 months for the local + HBI arm versus 6.3 months for patients in the local-only arm. Time-to-new treatment within the hemibody segment was also delayed. At one year, 76% of the local only group had been retreated versus 60% in the local + HBI arm. There were no fatalities and no radiation pneumonitis was seen in the local + HBI arm. Overall, the incidence of toxicities was low (5-15%). The occurrence of severe hematopoetic toxicities were significantly different in the local + HBI arm, but they were transitory. One life-threatening thrombocytopenia occurred, for a limited time, indicating excellent tolerance to HBI. This clinical trial demonstrates that HBI has the potential to be used to treat systemic and occult metastases, particularly if both halves of the body can be treated.
authors.affiliation: Dept. Radiation Oncology, University of Rochester, NY.
authors.forename: C A
authors.initials: CA
authors.lastname: Poulter
authors.forename: D
authors.initials: D
authors.lastname: Cosmatos
authors.forename: P
authors.initials: P
authors.lastname: Rubin
authors.forename: R
authors.initials: R
authors.lastname: Urtasun
authors.forename: J S
authors.initials: JS
authors.lastname: Cooper
authors.forename: R R
authors.initials: RR
authors.lastname: Kuske
authors.forename: N
authors.initials: N
authors.lastname: Hornback
authors.forename: C
authors.initials: C
authors.lastname: Coughlin
authors.forename: I
authors.initials: I
authors.lastname: Weigensberg
authors.forename: M
authors.initials: M
authors.lastname: Rotman
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D014916:Whole-Body Irradiation